Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 677

Sort by

Sort Order Select

Journal Articles

Notch1 mutation in B Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression

Ana M Hurtado López, Tzu Hua Chen-Liang, María Zurdo, Anna Puiggros, PhD, Andrea Gómez-Llonín, B.Sc., María-Dolores García-Malo, MD, Francisco José Ortuño, Vicente Vicente Garcia, MD PhD, Blanca Espinet, PhD, Andres Jerez

Blood (2019) 134 (Supplement_1): 851.

https://doi.org/10.1182/blood-2019-127960

Published: 2019

Journal Articles

Mitophagy Plays a Key Role in the Anti-Leukemic Activity of Autophagy Inhibitors Under Hypoxia in Acute Myeloid Leukemia

Hannah R.S. Fay, BS, Kaitlyn M. Dykstra, PhD, Matthew Johnson, Tara L. Cronin, BA, Linda Lutgen-Dunckley, Brandon L. Martens, BS, Joseph R. Moberg, BS, Monica L. Guzman, PhD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1278.

https://doi.org/10.1182/blood-2019-127024

Published: 2019

Journal Articles

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1277.

https://doi.org/10.1182/blood-2019-129762

Published: 2019

Journal Articles

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

Fumihiko Nakao, MD, Takuji Yamauchi, MD PhD, Yuichiro Semba, MD PhD, Jumpei Nogami, PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 912.

https://doi.org/10.1182/blood-2019-129237

Published: 2019

Journal Articles

Targeting Nicotinamide Adenine Dinucleotide (NAD) Glycohydrase Activity of CD38 Exerts Anti-Myeloma Effect Accompanying Intracellular NAD Elevation

Saki Kushima, Takayuki Sasano, Masao Matsuoka, MD PhD, Hiroyuki Hata, MD PhD, Yawara Kawano, MD PhD

Blood (2019) 134 (Supplement_1): 1810.

https://doi.org/10.1182/blood-2019-123624

Published: 2019

Journal Articles

Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia

Pu Zhang, Lindsey Brinton, PhD, James S. Blachly, MD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2019) 134 (Supplement_1): 2072.

https://doi.org/10.1182/blood-2019-129036

Published: 2019

Journal Articles

Targeting the Plasma Cell Specific Purine Metabolic Enzyme, AMPD1, Induces Multiple Myeloma Cell Death Accompanying NAD Depletion

Yawara Kawano, MD PhD, Takayuki Sasano, Saki Kushima, Yuki Inada, Nao Nishimura, MD, Hiroyuki Hata, MD PhD, Masao Matsuoka, MD PhD

Blood (2019) 134 (Supplement_1): 3097.

https://doi.org/10.1182/blood-2019-125756

Published: 2019

Journal Articles

Mn Porphyrin-Based Redox Active Drugs Improve Anemia and Reduce Organ Damage in a Murine Model of Sickle Cell Disease

Madhan Thamilarasan, PhD, Rodolfo Estupinan, Rahima Zennadi, PhD

Blood (2019) 134 (Supplement_1): 2255.

https://doi.org/10.1182/blood-2019-131140

Published: 2019

Journal Articles

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Dimitrios Papaioannou, MD, Deedra Nicolet, MS, Kellie J Archer, PhD, Allison Walker, Krzysztof Mrózek, MD PhD, Andrew J. Carroll, PhD, Jessica Kohlschmidt, PhD, Ann-Kathrin Eisfeld, MD, Marius Bill, MD PhD, Christopher J. Walker, PhD, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard Stone, MD, John C. Byrd, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2694.

https://doi.org/10.1182/blood-2019-125727

Published: 2019

Journal Articles

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Megha Ramappan, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 2670.

https://doi.org/10.1182/blood-2019-131949

Published: 2019

Journal Articles

CRISPR/Cas9 Mediated ELANE Knock-out Restores Survival and Granulocytic Differentiation of HL60 Cells Expressing Mutant Neutrophil Elastase: Is Neutrophil Elastase a Dispensible Granulocyte Protease?

Vahagn Makaryan, MD, Isabella N. Archibald, Merideth L. Kelley, MS, Breanna Fletcher, BSc, David C. Dale, MD

Blood (2019) 134 (Supplement_1): 435.

https://doi.org/10.1182/blood-2019-124988

Published: 2019

Journal Articles

T-Cell Derived Interferon Gamma Directly Targets Intestinal Epithelium to Induce Stem Cell Apoptosis in GI Gvhd

Shuichiro Takashima, MD PhD, Maria L. Martin, PhD, Suze A. Jansen, Ya-Yuan Fu, PhD, Anastasiya Egorova, Chen Liu, MD PhD, Richard Kolesnick, MD, Caroline A. Lindemans, MD, Alan M. Hanash, MD PhD

Blood (2019) 134 (Supplement_1): 585.

https://doi.org/10.1182/blood-2019-130811

Published: 2019

Journal Articles

Rara Is a Druggable Super-Enhancer Regulated Dependency in Pediatric AML

Alfred S. Daramola, MS, Monika Perez, BS, Oscar S. Sias-Garcia, MS, Maci S. Terrell, BS, Helen Y Wei, BS, Nikitha Cherayil, BS, Alexandra McLean Stevens, MD PhD, Charles Y Lin, PhD, Joanna S. Yi, MD

Blood (2019) 134 (Supplement_1): 281.

https://doi.org/10.1182/blood-2019-125425

Published: 2019

Journal Articles

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

Kohta Miyawaki, MD PhD, Takuji Yamauchi, MD PhD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Hiroaki Miyoshi, MD PhD, Simon Osborne, PhD, Deborah Taylor, PhD, Koichi Ohshima, MD PhD, Koji Kato, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 396.

https://doi.org/10.1182/blood-2019-129613

Published: 2019

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Blood (2019) 134 (Supplement_1): 4142.

https://doi.org/10.1182/blood-2019-126500

Published: 2019

Journal Articles

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3936.

https://doi.org/10.1182/blood-2019-131759

Published: 2019

Journal Articles

APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma

Lijie Xing, MD, Jiye Liu, PhD, Yuyin Li, PhD, Liang Lin, PhD, Kenneth Wen, Shih-Feng Cho, MD PhD, Tengteng Yu, MD PhD, Gang An, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4381.

https://doi.org/10.1182/blood-2019-130297

Published: 2019

Journal Articles

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Tarun K. Garg, PhD, Cody Ashby, PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Frits van Rhee, MD PhD, Shmuel Yaccoby, PhD

Blood (2019) 134 (Supplement_1): 4412.

https://doi.org/10.1182/blood-2019-127382

Published: 2019

Journal Articles

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4414.

https://doi.org/10.1182/blood-2019-122350

Published: 2019

Journal Articles

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Kensuke Kayamori, Cheng Zhong, Daisuke Shinoda, MD, Shuhei Koide, PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Naoya Mimura, MD PhD, Ryoji Ito, Kaoru Tohyama, MD PhD, William Lennox, Marla Weetall, PhD, Josephine Sheedy, BS, MSc, Emiko Sakaida, MD PhD, Koutaro Yokote, MD PhD, Atsushi Iwama, MD PhD

Blood (2019) 134 (Supplement_1): 5407.

https://doi.org/10.1182/blood-2019-125200

Published: 2019

NARROW

Notch1 mutation in B Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression

Mitophagy Plays a Key Role in the Anti-Leukemic Activity of Autophagy Inhibitors Under Hypoxia in Acute Myeloid Leukemia

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

Targeting Nicotinamide Adenine Dinucleotide (NAD) Glycohydrase Activity of CD38 Exerts Anti-Myeloma Effect Accompanying Intracellular NAD Elevation

Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia

Targeting the Plasma Cell Specific Purine Metabolic Enzyme, AMPD1, Induces Multiple Myeloma Cell Death Accompanying NAD Depletion

Mn Porphyrin-Based Redox Active Drugs Improve Anemia and Reduce Organ Damage in a Murine Model of Sickle Cell Disease

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

CRISPR/Cas9 Mediated ELANE Knock-out Restores Survival and Granulocytic Differentiation of HL60 Cells Expressing Mutant Neutrophil Elastase: Is Neutrophil Elastase a Dispensible Granulocyte Protease?

T-Cell Derived Interferon Gamma Directly Targets Intestinal Epithelium to Induce Stem Cell Apoptosis in GI Gvhd

Rara Is a Druggable Super-Enhancer Regulated Dependency in Pediatric AML

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only